Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 Days Inventory is 37.89 as of Jun. 2026, which is 7% above its 10-year median of 35.55. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 177 Medical Diagnostics & Research companies, GeneDx Holdings ranks better than 72.88% on this metric.
The historical rank and industry rank for GeneDx Holdings's Days Inventory or its related term are showing as below:
WGS'
s Days Inventory Range Over the Past 10 Years
Min: 31.93 Med: 35.55 Max: 51.98
Current: 34.89
During the past 7 years, GeneDx Holdings's highest Days Inventory was 51.98. The lowest was 31.93. And the median was 35.55.
WGS's Days Inventory is ranked better than 72.88% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.79
vs WGS: 34.89
GeneDx Holdings's Days Inventory
increased
from Jun. 2025 (35.30) to Jun. 2026 (37.89).
It might indicate that GeneDx Holdings's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
GeneDx Holdings's Inventory Turnover for the
three
months ended in Jun. 2026 was 2.41.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GeneDx Holdings's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.13.
GeneDx Holdings (NAS:WGS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
GeneDx Holdings's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GeneDx Holdings's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
GeneDx Holdings Days Inventory Related Terms
GeneDx Holdings Days Inventory Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GeneDx Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Days Inventory of 37.89 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on GeneDx Holdings and its competitors. This is near median its historical median of 35.55. Over the past decade, GeneDx Holdings' Days Inventory has ranged from 31.93 to 51.98. According to the industry distribution chart, GeneDx Holdings ranks #48 out of 177 companies in the Medical Diagnostics & Research industry, placing it in the top 27.1%.
Is GeneDx Holdings' Days Inventory too high?
GeneDx Holdings' current Days Inventory of 37.89 is near median its 10-year median of 35.55. Over the past 10 years, this metric has ranged from a low of 31.93 to a high of 51.98. The Medical Diagnostics & Research industry median Days Inventory is 67.79. GeneDx Holdings' value of 37.89 is 44.1% below this industry median. Based on the distribution chart, GeneDx Holdings ranks #48 out of 177 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Days Inventory compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #48 out of 177 companies for Days Inventory. This puts GeneDx Holdings in the upper half of its industry. The industry median Days Inventory is 67.79. GeneDx Holdings' value of 37.89 is 44.1% below this benchmark. Historically, GeneDx Holdings' own Days Inventory has ranged from 31.93 to 51.98 over the past decade. While the company's 10-year median is 35.55 vs. the industry median of 67.79, GeneDx Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 67.79, based on 177 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Days Inventory of 37.89 is 44.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 67.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Days Inventory is 37.89, which is near median its own 10-year median of 35.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Days Inventory is 37.89, which is near median its 10-year median of 35.55 and 44.1% below the Medical Diagnostics & Research industry median of 67.79. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Days Inventory is 37.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Days Inventory: 37.89 (near median its 10-year median of 35.55)
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
Industry Position: 44.1% below the Medical Diagnostics & Research median (#48 of 177)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
